Irritable Bowel Linked To Gut Bacteria, Definitively
Previous studies have suggested a link between gut bacteria and IBS, but they have been based on testing methane (a byproduct of bacterial fermentation) in the breath.
The findings, published in the May issue of Digestive Diseases and Sciences, corroborate those of previous clinical trials at Cedars-Sinai that showed antibiotics are effective against IBS.
Study author Mark Pimentel is director of the Cedars-Sinai GI Motility Program. He commented in a statement to the press released on Friday that:
"While we found compelling evidence in the past that bacterial overgrowth is a contributing cause of IBS, making this link through bacterial cultures is the gold standard of diagnosis."
"This clear evidence of the role bacteria play in the disease underscores our clinical trial findings, which show that antibiotics are a successful treatment for IBS," he added.
For the study, Pimentel and colleagues from Sismanogleion General Hospital in Athens, Greece, and from the University of Athens, examined samples of small bowel cultures from over 320 Greek patients to confirm the presence of small intestinal bacterial overgrowth (SIBO). The patients were all scheduled to receive upper gastrointestinal (GI) tract endoscopy.
They found that more than a third of the patients with IBS had SIBO, compared with only 10% of those without IBS.
Of patients with diarrhea-predominant form of IBS, 60% had SIBO, compared to just over 27% without the diarrhea form.
The researchers used the Rome II criteria to define IBS. The Rome criteria is a system, based on clinical symptoms, of classifying disorders of the digestive system in which symptoms can't be explained through presence of tissue abnormality. As well as IBS, other disorders that are defined using Rome criteria include dyspepsia, functional constipation, and functional heartburn.
Pimentel and colleagues conclude:
"Using culture of the small bowel, SIBO by aerobe bacteria is independently linked with IBS. These results reinforce results of clinical trials evidencing a therapeutic role of non-absorbable antibiotics for the management of IBS symptoms."
IBS is the most common gastrointestinal disorder in the US. Symptoms include painful bloating, constipation, diarrhea or an alternating pattern of both.
Many people with IBS avoid social interactions because they are embarassed by their symptoms.
Ten years ago Pimentel went against the thinking of the time when he proposed bacteria played a key role in IBS. Since then he has led clinical trials that have shown rifaximin, a targeted antibiotic absorbed only in the gut, is an effective treatment for IBS.
Pimentel said in the past, treatments have focused on alleviating symptoms. But "patients who take rifaximin experience relief of their symptoms even after they stop taking the medication".
"This new study confirms what our findings with the antibiotic and our previous studies always led us to believe: bacteria are key contributors to the cause of IBS," he affirmed.
Recommended related news
"The Prevalence of Overgrowth by Aerobic Bacteria in the Small Intestine by Small Bowel Culture: Relationship with Irritable Bowel
Syndrome"; Emmannouil Pyleris, Evangelos J. Giamarellos-Bourboulis, Dimitrios Tzivras, Vassilios Koussoulas, Charalambos Barbatzas and Mark
Pimentel; Digestive Diseases and Sciences, Volume 57, Number 5 (2012), 1321-1329; DOI: 10.1007/s10620-012-2033-7; Link to Abstract.
Additional source: Cedars-Sinai Medical Center
Please use one of the following formats to cite this article in your essay, paper or report:
Paddock, Catharine. "Irritable Bowel Linked To Gut Bacteria, Definitively." Medical News Today. MediLexicon, Intl., 26 May. 2012. Web.
27 Oct. 2016. <http://www.medicalnewstoday.com/articles/245874.php>
Paddock, C. (2012, May 26). "Irritable Bowel Linked To Gut Bacteria, Definitively." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
Contact our news editors
For any corrections of factual information, or to contact our editorial team, please see our contact page.
Copyright Medical News Today: Excluding email/sharing services explicitly offered on this website, material published on Medical News Today may not be reproduced, or distributed without the prior written permission of Medilexicon International Ltd. Please contact us for further details.